A relatively old drug -- metformin -- may hold the key to preventing life-threatening illness and bolstering human longevity, ...

New research reveals that metformin’s power may start in the brain, reshaping our understanding of blood sugar control and ...

Key takeaways: Metformin, FDA-approved to treat type 2 diabetes, may have CV benefits. The ongoing VA-IMPACT trial will assess metformin for people with prediabetes and ASCVD.

Metformin is used with diet and exercise to manage type 2 diabetes, and type 2 diabetes is a well-established risk factor for dementia, explained Hara, who was not part of the new study.

Metformin is the most commonly prescribed oral drug for diabetes. Of course, if you or a loved one receives treatment for diabetes, you probably already knew this. What you may not know, however, is ...

Several scientific studies show that the common diabetes drug Metformin can protect against dementia and Alzheimer’s.

The glucose-lowering effects of the first-line treatment for type 2 diabetes, metformin, have long been thought to be mediated through effects on liver cells, but new research suggests the drug ...

Patients with diabetes who use metformin for at least 5 consecutive years are less likely to develop AMD, particularly the ...

The Food and Drug Administration approved metformin for treating people with type 2 diabetes in 1994. It’s also frequently prescribed for those under age 60 with prediabetes.

Following early reports, 16 a meta-analysis of observational studies in individuals with type 2 diabetes associated metformin use with a 30% lower overall incidence of cancer compared with patients ...

Use of the diabetes drug metformin -- before a diagnosis of COVID-19 -- is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a new study ...

Diabetes was associated with a dramatic increase in mortality, with an odds ratio of 3.62. Overall, 67 percent of deaths in the study occurred in subjects with diabetes. The researchers looked at the ...